Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | 1.74% | 306.72 | 0.0% | $5163.15m | |
| BNTX | BioNTech SE | 3.17% | 344.06 | 0.0% | $1581.32m | |
| NVAX | Novavax, Inc. | -0.92% | 160.48 | 78.2% | $849.64m | |
| AMGN | Amgen, Inc. | 0.63% | 202.44 | 1.4% | $596.99m | |
| GILD | Gilead Sciences, Inc. | -0.16% | 69.56 | 1.0% | $508.98m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -0.31% | 203.81 | 1.9% | $477.50m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 0.18% | 635.16 | 2.7% | $474.90m | |
| LGVN | Longeveron Inc. | 11.78% | 20.12 | 0.0% | $401.25m | |
| ILMN | Illumina, Inc. | -2.85% | 347.28 | 3.3% | $315.98m | |
| SNSS | Sunesis Pharmaceuticals, Inc. | -4.21% | 4.10 | 0.7% | $286.61m | |
| BIIB | Biogen, Inc. | -2.01% | 223.92 | 1.8% | $273.37m | |
| OCGN | Ocugen, Inc. | -8.72% | 5.76 | 0.0% | $193.29m | |
| INCY | Incyte Corp. | -1.28% | 65.78 | 2.4% | $154.23m | |
| EXAS | EXACT Sciences Corp. | -4.94% | 76.59 | 18.0% | $148.34m | |
| SGEN | Seagen Inc. | -5.00% | 150.74 | 5.8% | $143.82m |
Company Profile
Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer; and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.